Intrexon | XON - Equity Capital And Reserves


Intrexon reported $43.17M in Equity Capital and Reserves for its fiscal quarter ending in June of 2024.





Equity Capital And Reserves Change Date
Agenus USD -271.11M 3.03M Dec/2025
Alaunos Therapeutics USD 2.8M 858K Sep/2025
Amgen USD 8.66B 961M Dec/2025
Anika Therapeutics USD 143.46M 3.34M Dec/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Heron Therapeutics USD 13.28M 1.6M Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
Intrexon USD 43.17M 75.33M Jun/2024
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Ligand Pharmaceuticals USD 1.02B 67.04M Dec/2025
MacroGenics USD 55.59M 11.41M Dec/2025
MannKind USD -51.02M 6.47M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Novartis USD 46.13B 1.38B Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Thermo Fisher Scientific USD 53.54B 2.38B Dec/2025
Veracyte USD 1.26B 36.61M Sep/2025
Xencor USD 635.59M 10.27M Dec/2025